GlycoMimetics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271
"At the ASH meeting in December, we showed that GMI-1271 was
well-tolerated and demonstrated a high remission rate among the patient
volunteers who were enrolled early in the study," said
GMI-1271 data were presented in 2016 at meetings of the
In addition to the ongoing Phase 1/2 trial, clinical investigators are
currently evaluating GMI-1271 in an ongoing Phase 1 clinical trial in
multiple myeloma. Preclinical data supporting the multiple myeloma study
is scheduled to be shared in an oral presentation at the
About AML
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow.
AML is the most common type of acute leukemia in adults. Each year in
About
GlycoMimetics is a clinical-stage biotechnology company focused on
cancer and sickle cell disease.
Forward-Looking Statements
This press release contains forward-looking statements regarding
GlycoMimetics' planned activities with respect to the clinical
development of its drug candidate, GMI-1271. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors, including the availability and
timing of data from ongoing clinical trials, the uncertainties inherent
in the initiation of future clinical trials, whether interim results
from a clinical trial will be predictive of the final results of the
trial or results of early clinical trials will be indicative of the
results of future trials, expectations for regulatory approvals,
availability of funding sufficient for GlycoMimetics' foreseeable and
unforeseeable operating expenses and capital expenditure requirements,
other matters that could affect the availability or commercial potential
of GlycoMimetics' drug candidates and other factors discussed in the
"Risk Factors" section of GlycoMimetics' Annual Report on Form 10-K that
was filed with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20170307005569/en/
For
Investors:
sannes@annesassociates.com
or
Media:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media